High-dose Sulbactam Treatment for Ventilator-Associated Pneumonia Caused by Carbapenem-Resistant Acinetobacter Baumannii / 대한중환자의학회지
Korean Journal of Critical Care Medicine
; : 308-316, 2016.
Article
em En
| WPRIM
| ID: wpr-24846
Biblioteca responsável:
WPRO
ABSTRACT
BACKGROUND:
Several antibiotics can be used to treat ventilator-associated pneumonia caused by carbapenem-resistant A. baumannii (CRAB-VAP) including high-dose sulbactam. However, the effectiveness of high-dose sulbactam therapy is not well known. We report our experience with high-dose sulbactam for treatment of CRAB-VAP.METHODS:
Medical records of patients with CRAB-VAP who were given high-dose sulbactam between May 2013 and June 2015 were reviewed.RESULTS:
Fifty-eight patients with CRAB-VAP were treated with high-dose sulbactam. The mean age was 72.0 ± 15.2 years, and the acute physiology and chronic health evaluation II (APACHE II) score was 15.1 ± 5.10 at the time of CRAB-VAP diagnosis. Early clinical improvement was observed in 65.5% of patients, and 30-day mortality was 29.3%. Early clinical failure (odds ratio [OR] 8.720, confidence interval [CI] 1.346-56.484; p = 0.023) and APACHE II score ≥ 14 at CRAB-VAP diagnosis (OR 10.934, CI 1.047-114.148; p = 0.046) were associated with 30-day mortality.CONCLUSIONS:
High-dose sulbactam therapy may be effective for the treatment of CRAB-VAP. However, early clinical failure was observed in 35% of patients and was associated with poor outcome.Palavras-chave
Texto completo:
1
Base de dados:
WPRIM
Assunto principal:
Acinetobacter
/
Sulbactam
/
Prontuários Médicos
/
Mortalidade
/
APACHE
/
Acinetobacter baumannii
/
Diagnóstico
/
Pneumonia Associada à Ventilação Mecânica
/
Antibacterianos
Tipo de estudo:
Diagnostic_studies
/
Prognostic_studies
Limite:
Humans
Idioma:
En
Revista:
Korean Journal of Critical Care Medicine
Ano de publicação:
2016
Tipo de documento:
Article